Pulmonary Fibrosis Clinical Trial
Official title:
Assessment of Peripheral Endothelial Function in Idiopathic Pulmonary Fibrosis
The aim of the study is to assess the peripheral endothelial function in adult patients with idiopathic pulmonary fibrosis (IPF) and the relationship between the peripheral endothelial function and the severity of the IPF.
The primary criteria is the peripheral endothelial function that will be assessed by the measure of flow-mediated dilation (reactive hyperemia-peripheral artery tone index). The pulmonary function will be assessed by the measures of the forced expiratory volume at one second (FEV1), the forced vital capacity (FVC) and the total lung capacity (TLC) and the diffusing capacity of the lung for carbon monoxide (DLCO). The dyspnea will be assessed with the New York Heart Association (NYHA) score. The exercise capacity will be assessed by the 6-min walk test. Pulmonary arterial pressure will be recorded through cardiac echography or catheterization. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04638517 -
The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis
|
Phase 2 | |
| Recruiting |
NCT05299333 -
Comparison of Pulmonary Telerehabilitation and Physical Activity Recommendations in Patients With Post Covid Fibrosis
|
N/A | |
| Terminated |
NCT04119115 -
Integrated Radiographic and Metabolomics Risk Assessment in Patients With Interstitial Lung Diseases
|
||
| Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
| Completed |
NCT01417156 -
Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174)
|
Phase 2 | |
| Terminated |
NCT00981747 -
Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis
|
Phase 2/Phase 3 | |
| Completed |
NCT00001596 -
Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome
|
Phase 2 | |
| Completed |
NCT00052052 -
An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
| Completed |
NCT01442779 -
Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
| Completed |
NCT00366509 -
Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
|
||
| Recruiting |
NCT00001532 -
Role of Genetic Factors in the Development of Lung Disease
|
||
| Recruiting |
NCT04767074 -
A Non-pharmacological Cough Control Therapy
|
N/A | |
| Recruiting |
NCT04864990 -
Dyspnea and Idiopathic Pulmonary Fibrosis
|
||
| Completed |
NCT01961362 -
Supplemental Oxygen in Pulmonary Fibrosis
|
||
| Completed |
NCT01271842 -
Long-term Outcome and Lung Capacity in Survivors of ARDS Due to Influenza A (H1N1) v2009 The RESPIFLU Study
|
N/A | |
| Completed |
NCT00650091 -
Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF
|
Phase 3 | |
| Active, not recruiting |
NCT00258544 -
Microarray Analysis of Gene Expression in Idiopathic Pulmonary Fibrosis (IPF)
|
||
| Enrolling by invitation |
NCT04930289 -
Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs
|
||
| Completed |
NCT02055222 -
Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease
|
||
| Enrolling by invitation |
NCT06327360 -
Illness Expectations in Pulmonary Fibrosis
|